Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer ; volume:19 ; number:1 ; day:24 ; month:1 ; year:2019 ; pages:1-14 ; date:12.2019
BMC cancer ; 19, Heft 1 (24.1.2019), 1-14, 12.2019
- Urheber
-
Mumin, Nuramalina H.
Drobnitzky, Neele
Patel, Agata
Lourenco, Luiza Madia
Cahill, Fiona F.
Jiang, Yanyan
Kong, Anthony
Ryan, Anderson J.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-019-5295-z
- URN
-
urn:nbn:de:101:1-2019030120331469779441
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mumin, Nuramalina H.
- Drobnitzky, Neele
- Patel, Agata
- Lourenco, Luiza Madia
- Cahill, Fiona F.
- Jiang, Yanyan
- Kong, Anthony
- Ryan, Anderson J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
HSP90 is essential for Jak-STAT signaling in classical Hodgkin lymphoma cells
HSP90 promotes tumor associated macrophage differentiation during triple-negative breast cancer progression
A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response
Modeling Heterogeneity of Triple‐Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug Resistance
Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms
HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation
Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance
DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
Intracellular signal transduction: the JAK-STAT pathway
JAK/STAT in leukemia: a clinical update
Phosphoregulation des Hsp90-Chaperonsystems
HSP90 is essential for Jak-STAT signaling in classical Hodgkin lymphoma cells
HSP90 promotes tumor associated macrophage differentiation during triple-negative breast cancer progression
A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response
Modeling Heterogeneity of Triple‐Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug Resistance
Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms
HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation
Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance
DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
Intracellular signal transduction: the JAK-STAT pathway
JAK/STAT in leukemia: a clinical update
Phosphoregulation des Hsp90-Chaperonsystems
HSP90 is essential for Jak-STAT signaling in classical Hodgkin lymphoma cells
HSP90 promotes tumor associated macrophage differentiation during triple-negative breast cancer progression
A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response
Modeling Heterogeneity of Triple‐Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug Resistance
Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms
HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation
Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance
DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
Intracellular signal transduction: the JAK-STAT pathway
JAK/STAT in leukemia: a clinical update